Development of Cost-Effective Nanocarriers for Targeted Drug Delivery in Cancer Therapy in India

Year : 2025 | Volume : 15 | Issue : 03 | Page : 1 7
    By

    Stephen Monday,

  • Atul Khajuria,

  • Eric Kwasi Elliason,

  • Gagan,

  • J. Samuel Kamanda,

  1. Teaching Assistant, Department of Allied Health Sciences, Desh Bhagat University, Mandi Gobindgarh, Pubjab, India
  2. Director, Department of Allied Health Sciences, Desh Bhagat University, Mandi Gobindgarh, Pubjab, India
  3. Teaching Assistant, Department of Allied Health Sciences, Desh Bhagat University, Mandi Gobindgarh, Pubjab, India
  4. Teaching Assistant, Department of Allied Health Sciences, Desh Bhagat University, Mandi Gobindgarh, Pubjab, India
  5. Teaching Assistant, Department of Allied Health Sciences, Desh Bhagat University, Mandi Gobindgarh, Pubjab, India

Abstract

The growing challenge of cancer in India demands the development of novel treatment approaches that are efficient and less expensive in alleviating disparities related to healthcare access and optimizing outcomes. Among the possible options, the drug delivery systems utilizing nanocarriers have been developed and they provide greater therapeutic targeting, reduced systemic toxicity, and decreased treatment costs over time. In this research, we assess the degrees of awareness, affordability, and acceptability of targeted nanocarrier drug delivery systems among cancer patients who are on medication and are receiving care at tertiary health facilities in various regions of India. A cross-sectional survey was conducted among 634 patients, who were randomly selected out of an estimated population of 375,000 individuals on drug-based cancer therapies. Data collection was done through a structured questionnaire that included demographics, treatment histories, economic challenges, and awareness and attitudes about nanomedicine. The results reveal that 72.6% of respondents had no prior awareness of nanocarrier-based therapies, yet 81.5% expressed willingness to participate in clinical trials involving cost-effective nanomedicine. Notably, 64.7% of participants reported significant financial constraints in managing ongoing treatments. There is a gap to be filled; it is clear from the findings that low cost, nanotechnology-based therapies should be added to cancer care services in the country alongside education and engagement strategies to promote further utilization.

Keywords: Cancer therapy, nanocarriers, targeted drug delivery, cost-effectiveness, India, chemotherapy, patient perception, nanomedicine, affordability, cancer burden

[This article belongs to Journal of Nanoscience, NanoEngineering & Applications ]

How to cite this article:
Stephen Monday, Atul Khajuria, Eric Kwasi Elliason, Gagan, J. Samuel Kamanda. Development of Cost-Effective Nanocarriers for Targeted Drug Delivery in Cancer Therapy in India. Journal of Nanoscience, NanoEngineering & Applications. 2025; 15(03):1-7.
How to cite this URL:
Stephen Monday, Atul Khajuria, Eric Kwasi Elliason, Gagan, J. Samuel Kamanda. Development of Cost-Effective Nanocarriers for Targeted Drug Delivery in Cancer Therapy in India. Journal of Nanoscience, NanoEngineering & Applications. 2025; 15(03):1-7. Available from: https://journals.stmjournals.com/jonsnea/article=2025/view=213446


References

  1. Ghosh A, Parida VK, Banerjee D. Challenges and opportunities on sustainable electrochemical transformations: application towards the synthesis of pharmaceuticals and precursors of drug-like molecules. Green Chemistry. 2024;26(10):5770-89.
  2. Datta SS, Ghose S, Ghosh M, Jain A, Mandal S, Chakraborty S, Caduff C. Journeys: understanding access, affordability and disruptions to cancer care in India. ecancermedicalscience. 2022 Jan 13;16:1342.
  3. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. Journal of drug targeting. 2016 Mar 15;24(3):179-91.
  4. Basile L, Pignatello R, Passirani C. Active targeting strategies for anticancer drug nanocarriers. Current drug delivery. 2012 May 1;9(3):255-68.
  5. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. Journal of occupational medicine and toxicology. 2007 Dec;2:1-6.
  6. Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, Xie J, Yang Z. Delivery of nanoparticles for treatment of brain tumor. Current Drug Metabolism. 2016 Oct 1;17(8):745-54.
  7. Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. International journal of nanomedicine. 2015 Feb 2:1001-18.
  8. Swain S, Kumar Sahu P, Beg S, Manohar Babu S. Nanoparticles for cancer targeting: current and future directions. Current drug delivery. 2016 Dec 1;13(8):1290-302.
  9. Ventola CL. The nanomedicine revolution: part 1: emerging concepts. Pharmacy and Therapeutics. 2012 Sep;37(9):512.
  10. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, Tan W. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine. 2012 Aug 1;7(8):1253-71.
  11. Thakuria A, Kataria B, Gupta D. Nanoparticle-based methodologies for targeted drug delivery—an insight. Journal of Nanoparticle Research. 2021 Apr;23(4):87.
Regular Issue Subscription Original Research
Volume 15
Issue 03
Received 14/04/2025
Accepted 17/05/2025
Published 17/06/2025
Publication Time 64 Days
151

Login


My IP

PlumX Metrics